TRIP study
Not Applicable
Recruiting
- Conditions
- HIV/AIDSCryptococcal Meningitis
- Registration Number
- PACTR201706002208408
- Lead Sponsor
- iverpool School of Tropical Medicine (LSTM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 620
Inclusion Criteria
The inclusion criteria will be:
-CD4<200 cells /¿l
-Serum/plasma CrAg positive
-Lumbar puncture negative
-Adult: ¿18y or more.
-Antiretroviral naïve (as reported by the patient)
-Planning to remain in the study area for about 6 months (as reported by the patient)
Exclusion Criteria
The exclusion criteria will be:
-requiring immediate in-patient care / admission
-Pregnant or lactating
-If ALT > 5 times upper limit of normal
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All-cause Mortality
- Secondary Outcome Measures
Name Time Method Patient retention on ART;costs of the strategies to the health service ;Assessment of enabling and barrier factors;pattern of re-organization of staffs roles
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the REMSTART package in PACTR201706002208408 target immune reconstitution and Cryptococcus in advanced HIV patients?
What is the comparative effectiveness of REMSTART versus standard ART protocols in reducing early mortality in Tanzania?
Which biomarkers predict response to REMSTART in HIV patients with Cryptococcal Meningitis (PACTR201706002208408)?
What adverse events are associated with REMSTART in Tanzanian HIV patients starting antiretroviral therapy (PACTR201706002208408)?
Are combination therapies or antifungals evaluated with REMSTART in PACTR201706002208408 for Cryptococcal Meningitis in HIV patients?